Want to see FR:ALVIO full AI Analyst Report?
ALVIO Stock Chart & Stats
€0.06
<€0.01(1.53%)
At close: 4:00 PM EST
€0.06
<€0.01(1.53%)
Day’s Range― - ―
52-Week Range€0.06 - €0.98
Previous CloseN/A
Volume8.86K
Average Volume (3M)1.36M
Market Cap
€379.43M
Enterprise Value€77.01M
Total Cash (Recent Filing)€1.05M
Total Debt (Recent Filing)€7.61M
Price to Earnings (P/E)―
Beta-0.76
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding499,448,300
10 Day Avg. Volume527,429
30 Day Avg. Volume1,357,798
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA ~40.6% revenue increase to ~€2.6M in 2025 signals expanding commercial or milestone receipts and greater program traction. For a clinical-stage biotech, durable top-line growth supports reinvestment, improves visibility on program economics and underpins longer-term operational scaling.
High Gross MarginsSustained ~67–71% gross margins indicate a favorable revenue mix (licensing/milestones vs high-cost manufacturing) and operational leverage potential. High margins provide a structural buffer as R&D spending fluctuates and help margins expand faster than revenues as commercial activities scale.
Positive Operating & Free Cash FlowTurning OCF and FCF positive after years of burn shows the business beginning to generate internal funding for operations. Durable cash generation reduces immediate refinancing needs, increases financial flexibility for trials or partnerships, and materially lowers solvency risk if sustained.
Bears Say
High LeverageA ~3.7x debt-to-equity ratio creates structural financial strain for a small biotech with lumpy revenues. Elevated leverage raises interest and covenant risks, limits ability to fund R&D internally, and increases likelihood of dilutive or costly financing if cash flows dip or development timelines extend.
Persistent Net LossesDespite revenue and margin improvements, a ~€4.9M net loss in 2025 shows the company has not yet achieved sustained profitability. Ongoing losses imply continued reliance on external capital to fund operations and expose equity holders to dilution or reprioritization of programs if funding tightens.
Clinical-stage, No Commercial ProductsBeing clinical-stage with no marketed products makes revenue streams small and milestone-dependent. This structural model yields lumpy cash receipts, high binary trial/regulatory risks, and dependence on partnerships or capital markets, limiting predictable long-term cash generation until commercialization.
ALVIO FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest stock price was €0.06 and its highest was €0.98 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €379.43M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 499,448,300 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in FR:ALVIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
GenSight Biologics SA
―
Cellectis SA
―